These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 34597912)

  • 21. Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma.
    Paiva B; Puig N; Cedena MT; Rosiñol L; Cordón L; Vidriales MB; Burgos L; Flores-Montero J; Sanoja-Flores L; Lopez-Anglada L; Maldonado R; de la Cruz J; Gutierrez NC; Calasanz MJ; Martin-Ramos ML; Garcia-Sanz R; Martinez-Lopez J; Oriol A; Blanchard MJ; Rios R; Martin J; Martinez-Martinez R; Sureda A; Hernandez MT; de la Rubia J; Krsnik I; Moraleda JM; Palomera L; Bargay J; Van Dongen JJM; Orfao A; Mateos MV; Blade J; San-Miguel JF; Lahuerta JJ;
    J Clin Oncol; 2020 Mar; 38(8):784-792. PubMed ID: 31770060
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New Developments in Diagnosis, Prognosis, and Assessment of Response in Multiple Myeloma.
    Landgren O; Rajkumar SV
    Clin Cancer Res; 2016 Nov; 22(22):5428-5433. PubMed ID: 28151710
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials.
    Lahuerta JJ; Paiva B; Vidriales MB; Cordón L; Cedena MT; Puig N; Martinez-Lopez J; Rosiñol L; Gutierrez NC; Martín-Ramos ML; Oriol A; Teruel AI; Echeveste MA; de Paz R; de Arriba F; Hernandez MT; Palomera L; Martinez R; Martin A; Alegre A; De la Rubia J; Orfao A; Mateos MV; Blade J; San-Miguel JF;
    J Clin Oncol; 2017 Sep; 35(25):2900-2910. PubMed ID: 28498784
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.
    Mina R; Musto P; Rota-Scalabrini D; Paris L; Gamberi B; Palmas A; Aquino S; de Fabritiis P; Giuliani N; De Rosa L; Gozzetti A; Cellini C; Bertamini L; Capra A; Oddolo D; Vincelli ID; Ronconi S; Pavone V; Pescosta N; Cea M; Fioritoni F; Ballanti S; Grasso M; Zamagni E; Belotti A; Boccadoro M; Gay F
    Lancet Oncol; 2023 Jan; 24(1):64-76. PubMed ID: 36528035
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial.
    Kazandjian D; Hill E; Dew A; Morrison C; Roswarski J; Korde N; Emanuel M; Petrosyan A; Bhutani M; Calvo KR; Dulau-Florea A; Kwok M; Lee MJ; Lee S; Lindenberg L; Mailankody S; Manasanch E; Maric I; Mena E; Patel N; Tageja N; Trepel JB; Turkbey B; Wang HW; Wang W; Yuan C; Zhang Y; Braylan R; Choyke P; Stetler-Stevenson M; Steinberg SM; Figg WD; Roschewski M; Landgren O
    JAMA Oncol; 2021 Nov; 7(11):1678-1685. PubMed ID: 34529025
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Utility and feasibility of a six-color multiparametric flow cytometry for measurable residual disease analysis in plasma cell myeloma in resource-limited settings with 5-year survival data.
    Sharma P; Singh Sachdeva MU; Varma N; Bose P; Aggarwal R; Malhotra P
    J Cancer Res Ther; 2021; 17(6):1515-1520. PubMed ID: 34916387
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current Approach to Managing Patients with Newly Diagnosed High-Risk Multiple Myeloma.
    Marneni N; Chakraborty R
    Curr Hematol Malig Rep; 2021 Apr; 16(2):148-161. PubMed ID: 33876390
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MRD Assessment in Multiple Myeloma: Progress and Challenges.
    Bertamini L; D'Agostino M; Gay F
    Curr Hematol Malig Rep; 2021 Apr; 16(2):162-171. PubMed ID: 33950462
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of new treatment approaches in defining treatment goals in multiple myeloma--the ultimate goal is extended survival.
    Durie BG
    Cancer Treat Rev; 2010 May; 36 Suppl 2():S18-23. PubMed ID: 20472184
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Requirements for operational cure in multiple myeloma.
    Mohty M; Avet-Loiseau H; Harousseau JL
    Blood; 2021 Oct; 138(16):1406-1411. PubMed ID: 34324647
    [TBL] [Abstract][Full Text] [Related]  

  • 31. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials.
    Costa LJ; Derman BA; Bal S; Sidana S; Chhabra S; Silbermann R; Ye JC; Cook G; Cornell RF; Holstein SA; Shi Q; Omel J; Callander NS; Chng WJ; Hungria V; Maiolino A; Stadtmauer E; Giralt S; Pasquini M; Jakubowiak AJ; Morgan GJ; Krishnan A; Jackson GH; Mohty M; Mateos MV; Dimopoulos MA; Facon T; Spencer A; Miguel JS; Hari P; Usmani SZ; Manier S; McCarthy P; Kumar S; Gay F; Paiva B
    Leukemia; 2021 Jan; 35(1):18-30. PubMed ID: 32778736
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
    Korde N; Roschewski M; Zingone A; Kwok M; Manasanch EE; Bhutani M; Tageja N; Kazandjian D; Mailankody S; Wu P; Morrison C; Costello R; Zhang Y; Burton D; Mulquin M; Zuchlinski D; Lamping L; Carpenter A; Wall Y; Carter G; Cunningham SC; Gounden V; Sissung TM; Peer C; Maric I; Calvo KR; Braylan R; Yuan C; Stetler-Stevenson M; Arthur DC; Kong KA; Weng L; Faham M; Lindenberg L; Kurdziel K; Choyke P; Steinberg SM; Figg W; Landgren O
    JAMA Oncol; 2015 Sep; 1(6):746-54. PubMed ID: 26181891
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early Intervention With a Curative Intent Through an Intensive Therapy Versus Immunologic Disease Control Using a Minimal Intensity Approach in the Management of High-risk Smoldering Multiple Myeloma: A Systematic Review of Evidence From Clinical Trials.
    Ojo AS; Akinyemi O; Araoye MO; Ali A
    Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):e27-e40. PubMed ID: 36402701
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration.
    Anderson KC; Auclair D; Adam SJ; Agarwal A; Anderson M; Avet-Loiseau H; Bustoros M; Chapman J; Connors DE; Dash A; Di Bacco A; Du L; Facon T; Flores-Montero J; Gay F; Ghobrial IM; Gormley NJ; Gupta I; Higley H; Hillengass J; Kanapuru B; Kazandjian D; Kelloff GJ; Kirsch IR; Kremer B; Landgren O; Lightbody E; Lomas OC; Lonial S; Mateos MV; Montes de Oca R; Mukundan L; Munshi NC; O'Donnell EK; Orfao A; Paiva B; Patel R; Pugh TJ; Ramasamy K; Ray J; Roshal M; Ross JA; Sigman CC; Thoren KL; Trudel S; Ulaner G; Valente N; Weiss BM; Zamagni E; Kumar SK
    Clin Cancer Res; 2021 Oct; 27(19):5195-5212. PubMed ID: 34321279
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New criteria for response assessment: role of minimal residual disease in multiple myeloma.
    Paiva B; van Dongen JJ; Orfao A
    Blood; 2015 May; 125(20):3059-68. PubMed ID: 25838346
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enrichment of circulating myeloma cells by immunomagnetic beads combined with flow cytometry for monitoring minimal residual disease and relapse in patients with multiple myeloma.
    Wang N; Tesfaluul N; Li J; Gao X; Liu S; Yue B
    Ann Hematol; 2019 Dec; 98(12):2769-2780. PubMed ID: 31748925
    [TBL] [Abstract][Full Text] [Related]  

  • 37. International Myeloma Working Group recommendations for global myeloma care.
    Ludwig H; Miguel JS; Dimopoulos MA; Palumbo A; Garcia Sanz R; Powles R; Lentzsch S; Ming Chen W; Hou J; Jurczyszyn A; Romeril K; Hajek R; Terpos E; Shimizu K; Joshua D; Hungria V; Rodriguez Morales A; Ben-Yehuda D; Sondergeld P; Zamagni E; Durie B
    Leukemia; 2014 May; 28(5):981-92. PubMed ID: 24177258
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Roundtable: How I treat a newly diagnosed patient with high-risk myeloma.
    Kaufman JL
    Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):120-124. PubMed ID: 31808841
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Impact of minimal residual disease detection after treatment of multiple myeloma].
    Szendrei T; Plander M; Szabó Z; Kereskai L; Kajtár B; Papp G; Iványi JL
    Orv Hetil; 2019 Mar; 160(13):502-508. PubMed ID: 30907098
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics.
    Chakraborty R; Muchtar E; Kumar SK; Jevremovic D; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Gertz MA
    Biol Blood Marrow Transplant; 2017 Apr; 23(4):598-605. PubMed ID: 28115277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.